COMP <GO>
RVTY vs BIO // FREE CASH FLOW YIELD
Revvity Inc. (NYSE) VS. Bio-Rad Laboratories Inc. (NYSE) • 15-METRIC TALLY: RVTY 7
— BIO 5
▲ FREE CASH FLOW YIELD LEADER: BIO
LAST: $151.60 (-3.44%) • MKT CAP: $17.52B
fcf-yield
2.75%
LAST: $366.16 (-1.62%) • MKT CAP: $9.95B
fcf-yield
3.64%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RVTY VS. BIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RVTY | BIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 51.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.10% | 0.50% | +2.60 | RVTY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 48.2x | 60.4x | -12.20 | RVTY | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 2.75% | 3.64% | -0.89 | BIO | /fcf-yield <GO> |
| Operating Margin | 12.50% | 1.80% | +10.70 | RVTY | /operating-margins <GO> |
| Net Profit Margin | 8.40% | 29.40% | -21.00 | BIO | /net-margins <GO> |
| Revenue Growth (YoY) | 3.70% | 0.70% | +3.00 | RVTY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.18% | 0.00% | +0.18 | RVTY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.37 | 3.59 | -0.22 | BIO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.9 | 50.1 | +1.80 | RVTY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.04 | -0.09 | BIO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 71.3x | 12.6x | +58.70 | BIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $17.52B | $9.95B | $7.57B | RVTY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RVTY REV | BIO REV | RVTY GROSS % | BIO GROSS % | RVTY FCF | BIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.86B | $2.58B | — | 51.9% | $509.4M | $374.6M |
| FY 2024 | $2.76B | $2.57B | — | 53.7% | $541.7M | $289.6M |
| FY 2023 | $2.75B | $2.67B | — | — | -$32.5M | $254.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RVTY // BETA 0.95
BIO // BETA 1.04